Literature DB >> 25787043

Aldosterone and abnormal left ventricular geometry in chronic kidney disease.

Cesare Cuspidi1, Marijana Tadic2, Carla Sala3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25787043     DOI： 10.1038/hr.2015.34

Source DB:  PubMed          Journal:  Hypertens Res        ISSN： 0916-9636            Impact factor:   3.872


× No keyword cloud information.
  12 in total

1.  Night-time blood pressure is associated with the development of chronic kidney disease in a general population: the Ohasama Study.

Authors:  Atsuhiro Kanno; Masahiro Kikuya; Kei Asayama; Michihiro Satoh; Ryusuke Inoue; Miki Hosaka; Hirohito Metoki; Taku Obara; Haruhisa Hoshi; Kazuhito Totsune; Toshinobu Sato; Yoshio Taguma; Hiroshi Sato; Yutaka Imai; Takayoshi Ohkubo
Journal:  J Hypertens       Date:  2013-12       Impact factor: 4.844

2.  Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease.

Authors:  Giuseppe Mulè; Emilio Nardi; Laura Guarino; Valentina Cacciatore; Giulio Geraci; Ilenia Calcaterra; Bruno Oddo; Francesco Vaccaro; Santina Cottone
Journal:  Hypertens Res       Date:  2015-01-08       Impact factor: 3.872

3.  A multi-marker approach to predict incident CKD and microalbuminuria.

Authors:  Caroline S Fox; Philimon Gona; Martin G Larson; Jacob Selhub; Geoffrey Tofler; Shih-Jen Hwang; James B Meigs; Daniel Levy; Thomas J Wang; Paul F Jacques; Emelia J Benjamin; Ramachandran S Vasan
Journal:  J Am Soc Nephrol       Date:  2010-10-21       Impact factor: 10.121

4.  Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance.

Authors:  Joanna Burns; Stephen G Ball; Gillian Worthy; Allan D Struthers; David A S G Mary; John P Greenwood
Journal:  J Hypertens       Date:  2012-10       Impact factor: 4.844

5.  Effects of salt status and blockade of mineralocorticoid receptors on aldosterone-induced cardiac injury.

Authors:  Takuya Hattori; Tamayo Murase; Yukino Sugiura; Kai Nagasawa; Keiji Takahashi; Masafumi Ohtake; Mayuko Ohtake; Masaaki Miyachi; Toyoaki Murohara; Kohzo Nagata
Journal:  Hypertens Res       Date:  2013-09-19       Impact factor: 3.872

6.  Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.

Authors:  Casper N Bang; Eva Gerdts; Gerard P Aurigemma; Kurt Boman; Giovanni de Simone; Björn Dahlöf; Lars Køber; Kristian Wachtell; Richard B Devereux
Journal:  Circ Cardiovasc Imaging       Date:  2014-04-10       Impact factor: 7.792

7.  Nighttime blood pressure and new-onset left ventricular hypertrophy: findings from the Pamela population.

Authors:  Cesare Cuspidi; Rita Facchetti; Michele Bombelli; Carla Sala; Francesca Negri; Guido Grassi; Giuseppe Mancia
Journal:  Hypertension       Date:  2013-05-20       Impact factor: 10.190

8.  Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-β1/Smad signal pathway.

Authors:  Yong Zhang; Liang Shao; Aiqun Ma; Gongchang Guan; Junkui Wang; Yaping Wang; Gang Tian
Journal:  Hypertens Res       Date:  2013-10-03       Impact factor: 3.872

9.  Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism.

Authors:  Gian Paolo Rossi; Maurizio Cesari; Cesare Cuspidi; Giuseppe Maiolino; Maria Verena Cicala; Valeria Bisogni; Franco Mantero; Achille C Pessina
Journal:  Hypertension       Date:  2013-05-06       Impact factor: 10.190

10.  Relations of biomarkers representing distinct biological pathways to left ventricular geometry.

Authors:  Raghava S Velagaleti; Philimon Gona; Daniel Levy; Jayashri Aragam; Martin G Larson; Geoffrey H Tofler; Wolfgang Lieb; Thomas J Wang; Emelia J Benjamin; Ramachandran S Vasan
Journal:  Circulation       Date:  2008-11-10       Impact factor: 29.690
View more
  3 in total

1.  Dual inhibitory action on aldosterone by combined angiotensin receptor antagonism and neprilysin inhibition.

Authors:  Kouichi Tamura; Ryu Kobayashi; Sona Haku; Kengo Azushima; Hiromichi Wakui
Journal:  Hypertens Res       Date:  2016-06-23       Impact factor: 3.872

Review 2.  Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?

Authors:  Ali Nehme; Kazem Zibara
Journal:  Hypertens Res       Date:  2017-07-06       Impact factor: 3.872

3.  The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.

Authors:  Shin-Ichiro Miura; Yasunori Suematsu; Yoshino Matsuo; Sayo Tomita; Asuka Nakayama; Masaki Goto; Tadaaki Arimura; Takashi Kuwano; Eiji Yahiro; Keijiro Saku
Journal:  Hypertens Res       Date:  2016-06-23       Impact factor: 3.872
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.